- Showcases Allplex™ HPV merchandise designed to check for 14 high-risk HPV genotypes
- Advocates HPV testing for early analysis and prevention of cervical most cancers
- Goals to speed up the widespread adoption of syndromic PCR testing to create “a world free from all illnesses”
SEOUL, South Korea, July 16, 2024 /PRNewswire/ — Seegene Inc. (KQ096530), a number one South Korean firm offering a complete answer for PCR molecular diagnostics, demonstrated its human papillomavirus (HPV) diagnostic merchandise and underscored the vital significance of HPV screening check on the Asia-Oceania Analysis Group in Genital An infection and Neoplasia (AOGIN) convention, held in Seoul, South Korea from July 11-13.
Seegene displays its sales space and demonstrates the HPV diagnostic merchandise with STARlet-AIOS™ at AOGIN 2024 on Thursday, July 11-13, 2024
On the AOGIN, Seegene introduced its superior applied sciences for figuring out viruses linked to cervical most cancers. The corporate organized an exhibition sales space and hosted a symposium session beneath the theme of ‘Navigating scientific pointers and implementations for HPV cervical most cancers screening.’
The corporate showcased its distinctive quantitative PCR technology-based HPV diagnostic merchandise, ‘Allplex™ HPV HR Detection’ and ‘Allplex™ HPV28 Detection’. The Allplex™ HPV HR Detection is designed to check for 14 high-risk HPVs, together with varieties 16 and 18, in a single tube. The Allplex™ HPV28 Detection is designed to check for 28 HPVs, in two tubes, together with 19 high-risk varieties and 9 low-risk varieties, in two tubes. The merchandise are perfect for cervical most cancers prevention and follow-up administration.
The corporate additionally launched Seegene’s STARlet-AIOS™, a totally automated molecular diagnostic testing system that streamlines all the PCR course of from nucleic acid extraction to outcome evaluation, together with SG STATS, the corporate’s premium platform of superior statistical evaluation.
On the symposium session hosted by Seegene on July 11, Dr. Lan Xu from the Shanghai Jiao Tong College of Public Well being in China introduced a lecture on “Scientific validation of human papillomavirus assays for cervical most cancers screening through the VALGENT framework.” Dr. Shin-Wha Lee from the Asan Medical Heart and College of Ulsan in Korea confirmed her examine on “Incorporating HPV testing with genotypes in population-based screening applications.”
“At AOGIN, we had been capable of showcase the excellence of Seegene’s PCR testing expertise and HPV merchandise. We anticipate our HPV merchandise to be adopted in cervical most cancers screening applications in additional international locations,” stated Daniel Shin, Govt Vice-President and Chief International Gross sales and Advertising and marketing Officer at Seegene. “We’re at present working a marketing campaign within the world market to boost consciousness about the advantages of syndromic PCR testing, together with simultaneous testing for HPV and sexually transmitted infections (STIs). We imagine the marketing campaign will pave the way in which for the widespread adoption of syndromic PCR testing, serving to to comprehend “a world free from all illnesses.”
Seegene’s syndromic quantitative PCR expertise is simultaneous multiplex molecular diagnostic expertise primarily based on real-time PCR. It permits for the detection of assorted pathogens inflicting comparable signs in a single tube, facilitating quick and correct analysis. Moreover, analyzing the cycle threshold (Ct) worth helps decide the extent of the an infection, which boosts medical follow. Seegene is the primary to globally commercialize ‘3 Ct’ expertise, which may present the Ct worth of three targets in a single channel.
Cervical most cancers is the fourth commonest most cancers amongst girls worldwide, with the second-highest mortality price. In line with the World Well being Group (WHO), roughly 600,000 girls are newly recognized with cervical most cancers every year globally, leading to 340,000 deaths. Within the Asia-Pacific area alone, about 270,000 girls are recognized yearly, with over 140,000 deaths reported. The WHO has set a goal to attain 70% cervical most cancers screening protection by 2030, a major enhance from the present 20%. In 2020, solely 33% of girls had been screened for cervical most cancers no less than as soon as.
There are about 200 HPV genotypes, of which 99.8% of cervical cancers are attributable to HPV. Sorts 16 and 18 account for 70% of cervical most cancers, whereas 19 high-risk varieties are liable for 90% of all most cancers instances. The development to most cancers depends upon the genotype of the HPV an infection, the extent of the an infection and co-infection. Since most HPV infections don’t current clear signs, correct detection is vital for the early analysis of cervical most cancers. Lately, many international locations have been recommending HPV testing as a substitute of the Pap smear for cervical most cancers screening.
About Seegene
Seegene has 23 years of devoted R&D, manufacturing, and enterprise expertise round syndromic quantitative PCR applied sciences, which was highlighted throughout the COVID-19 pandemic when it offered over 340 million COVID-19 assessments to greater than 100 international locations worldwide. The core function of Seegene’s distinctive syndromic PCR applied sciences is the power to concurrently check 14 pathogens that trigger comparable signs in a single tube and supply quantitative data on the infectivity profile to correlate with the severity of sickness.
About AOGIN 2024
The AOGIN, based in 2004, contains of 25 member international locations in Asia and Oceania. The group hosts worldwide educational conferences targeted on the therapy and prevention of cervical most cancers. This yr’s convention in Seoul attracted over 500 consultants from 22 international locations, together with China, Japan, and India, who shared the newest analysis findings and scientific practices relating to HPV.
